As 49% of the primary malignant melanomas and 67% of the metastatic melanomas evaluated in this study expressed FOXM1, it would be inappropriate for all patients with melanoma to be treated with FOXM1-targeted immunotherapy. The gene discussed is FOXM1; the disease is melanoma.